Petrelintide Heads to Phase 3, Raising the Bar for Peptide Scale-Up

Zealand Pharma and Roche have formally endorsed advancement of petrelintide, a long-acting amylin analog, into Phase 3 trials for chronic weight management, with initiation planned for the second half of 2026. For peptide CDMOs and formulation teams, the move signals an imminent demand for scalable manufacturing of a molecule engineered for once-weekly subcutaneous delivery -- a profile that carries distinct stability and co-formulation requirements not typical of first-generation GLP-1 therapies.

Petrelintide has been designed with chemical and physical stability and no fibrillation around neutral pH, a property that enables co-formulation and co-administration with other peptides. That specification is directly relevant to the parallel development track: a Phase 2 trial evaluating petrelintide in combination with Roche's GLP-1/GIP receptor dual agonist enicepatide (CT-388) is planned for initiation in the second quarter of 2026. Manufacturing teams preparing for combination peptide products will need to demonstrate formulation compatibility and sustained stability across both molecules under GMP conditions consistent with ICH Q10 quality system expectations.

Phase 2 data context: The ZUPREME-1 Phase 2 trial showed double-digit weight loss with placebo-like tolerability for petrelintide as monotherapy. The Phase 3 program is designed to evaluate efficacy, safety, and tolerability in adults living with obesity or overweight with weight-related comorbidities, administered once weekly via subcutaneous injection. Tolerability and long-term adherence are cited as primary differentiators, factors that will also influence labeling negotiations and post-approval commitments under 21 CFR Part 211 process validation requirements as the program matures.

Amylin, the endogenous peptide petrelintide is modeled on, is produced in pancreatic beta cells and co-secreted with insulin in response to ingested nutrients. Receptor activation has been shown to reduce body weight by restoring sensitivity to the satiety hormone leptin and inducing earlier satiety signals. Zealand Pharma brings more than 25 years of peptide R&D experience to the program, and the collaboration with Roche, established in 2025 under an exclusive co-development and co-commercialization agreement, positions both companies to pursue petrelintide across monotherapy and combination indications.

Source: Zealand Pharma Company Announcement No. 11/2026, published via GlobeNewswire, April 29, 2026.